Company Overview
Kyverna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing cell therapies specifically designed for patients suffering from autoimmune diseases. The company's primary focus centers on its lead product candidate, KYV-101, which is an autologous CD19 CAR T-cell product intended for the treatment of conditions such as stiff person syndrome and myasthenia gravis. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, a landscape defined by high research and development expenditures and the pursuit of novel therapeutic modalities. With a reported market capitalization of $469.10M, a workforce of 129 employees, and N/A for annual revenue, the company's financial scale reflects the typical characteristics of a pre-commercial biotech firm where valuation is driven by pipeline potential rather than current cash flow generation. The absence of significant revenue figures in the TTM period indicates that the company is currently in a development phase, prioritizing clinical progress over commercial scaling, which is standard for clinical-stage entities focusing on complex cell therapy products.
Financial Health
The company reports N/A for revenue over the trailing twelve months, while its net income stands at a loss of $-160,992,000 and EBITDA is reported at $-170,456,992. The substantial gap between the non-existent revenue and the large net income loss reveals a cost structure dominated by high operational and research expenses typical of drug development, rather than costs associated with sales and marketing. Free cash flow is reported at $-95,628,248, which indicates that the company is consuming its cash reserves to fund operations and development activities, thereby limiting immediate financial flexibility for dividends or acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that signifies the company has not yet generated sufficient revenue to establish a profitable margin structure or cover its variable and fixed costs. On the balance sheet, the company holds $171.14M in cash against $5.02M in debt, supported by a debt-to-equity ratio of 3.31, suggesting a leveraged capital structure where equity is relatively small compared to the debt load. Despite the reported debt, the current ratio of 5.16 demonstrates strong short-term liquidity, indicating that the company possesses more than five times the current assets necessary to meet its short-term obligations. Return on Equity is -70.8% and Return on Assets is -40.7%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common scenario for biotech firms in the clinical stage where capital is burned to advance product candidates through regulatory pathways.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is listed as -2.32, a negative figure that implies the market is pricing in future earnings that are not yet realized or are currently negative. The price-to-book ratio stands at 2.27, indicating that the market values the company at more than twice its book value, reflecting a premium placed on the intellectual property and clinical potential of the pipeline rather than existing assets. The price-to-sales ratio is N/A because there is no reported sales data, and the EV/EBITDA multiple is -1.05, suggesting that valuation models relying on earnings multiples are currently inapplicable or require normalization for the company's specific loss-making status. Regarding trading range, the stock has a 52-week high of $13.67 and a 52-week low of $1.78, placing the current market price in a wide volatility band that reflects the speculative nature of clinical-stage biotechnology investments. The beta value is 3.35, which signifies that the stock price is expected to be significantly more volatile than the broader market, moving with high sensitivity to sector-specific news and general market sentiment fluctuations.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, reflecting the company's current stage where historical financial data is not yet established for comparative analysis. Because there is no revenue to grow, the comparison of earnings growth versus revenue growth is not applicable, but the company's financial trajectory is entirely dependent on the successful progression of its clinical trials rather than commercial sales expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow and existing capital are reinvested directly into research, development, and operational scaling. Consequently, the overall growth and income profile of Kyverna Therapeutics is characterized by a total reliance on capital markets for funding and a complete absence of income distribution to shareholders, aligning the interests of investors strictly with the long-term clinical success of the KYV-101 product candidate.